Online Only Articles

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Cancer Resarch and Biostatistics, Seattle, WA, USA
Cancer Resarch and Biostatistics, Seattle, WA, USA
Adaptive Biotechnologies, San Francisco, CA, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Adaptive Biotechnologies, San Francisco, CA, USA
Adaptive Biotechnologies, San Francisco, CA, USA
Mt. Sinai School of Medicine, New York, NY, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Vol. 102 No. 8 (2017): August, 2017 https://doi.org/10.3324/haematol.2017.165217